What are the diagnostic criteria for cytokine release syndrome in lymphoma patients?

Diagnostic Criteria for Cytokine Release Syndrome in Lymphoma

Cytokine release syndrome in lymphoma patients is diagnosed using the American Society for Transplantation and Cellular Therapy (ASTCT) consensus criteria, which define CRS as "a supraphysiologic response following any immune therapy that results in the activation or engagement of endogenous or infused T cells and/or other immune effector cells," with fever being the cardinal diagnostic feature. 1

Core Diagnostic Definition

• The ASTCT consensus criteria should be used for CRS diagnosis to ensure comparability across studies and treatment centers. 2
• The Common Terminology Criteria for Adverse Events (CTCAE) defines CRS as "a disorder characterized by fever, tachypnea, headache, tachycardia, hypotension, rash, and/or hypoxia caused by the release of cytokines." 1
• CRS is fundamentally caused by cytokine release from bystander immune and non-immune cells following immunotherapy, including CAR T-cell therapy and bispecific antibodies. 1

Clinical Presentation Required for Diagnosis

The presenting symptoms that establish CRS diagnosis in lymphoma patients include: 1

• Fever (mandatory cardinal feature)
• Tachycardia
• Hypoxia
• Tachypnea
• Hypotension
• Headache
• Nausea
• Rash
• Shortness of breath
• Respiratory failure (in severe cases)

Temporal Characteristics

• CRS onset is variable depending on the specific therapy, with peaks typically occurring 2-7 days after infusion. 1
• Delays of up to 3 weeks have been reported, requiring extended monitoring periods. 1
• Patients should remain within 2 hours of the treating center for 4-8 weeks post-therapy and return immediately upon experiencing fever or other toxicities. 1

Grading Systems and Their Concordance

Three major grading scales exist (Penn, Lee, and ASTCT), but they show significant discordance: 3

• In the JULIET trial analysis, the Lee scale yielded concordance for only 39 events, lower grade for 20 events, and higher grade for 5 events compared with the Penn scale. 3
• The ASTCT criteria provided concordance for 37 events, lower grade for 23 events, and higher grade for 4 events compared with the Penn scale. 3
• Despite these differences, the ASTCT criteria are recommended as the standard for consistency across institutions. 2

Critical Differential Diagnosis Considerations

CRS must be distinguished from several mimicking conditions that present similarly in lymphoma patients:

Sepsis and Infection

• Patients receiving CAR T-cell therapy face dual risks of CRS and sepsis, with significantly overlapping clinical presentations. 2
• In post-bone marrow transplant patients with grade 3 CRS, a thorough infectious workup should be performed including blood and urine cultures, chest imaging, and viral screening. 4
• Empiric broad-spectrum antibiotics should be commenced while awaiting culture results due to high infection risk in immunocompromised patients, even when CRS is suspected. 4

Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

• CRS-related headache must be distinguished from ICANS, which presents with more severe neurological symptoms including encephalopathy, aphasia, altered consciousness, cognitive impairment, motor weakness, and seizures. 1
• While headache alone is typically part of CRS, persistent or severe headache with additional neurological symptoms should prompt evaluation for ICANS. 1
• Neurological consultation and additional workup including MRI and lumbar puncture may be warranted if ICANS is suspected. 1

Biomarker Support for Diagnosis

While not required for diagnosis, biomarkers help confirm CRS and predict severity: 2

• Extremely elevated IL-6 levels (>2000 pg/mL) indicate severe inflammatory states with high mortality risk. 2
• The NCCN recommends using combinatorial biomarker models including IL-6, IFN-γ, ferritin, and CRP to predict severe CRS before clinical deterioration. 2
• Procalcitonin can be elevated during severe inflammatory states even without bacterial infection, particularly in grade 3 CRS where massive cytokine release mimics bacterial sepsis. 4

Special Considerations in Lymphoma Populations

• CRS occurred in 48.3% of Chinese patients receiving CD3 × CD20 bispecific antibodies, with grade ≥2 CRS associated with bulky disease (>5 cm), ≥3 previous treatment lines, elevated monocyte-to-lymphocyte ratio, and low platelet count. 5
• In the JULIET trial of tisagenlecleucel for diffuse large B-cell lymphoma, 64 of 111 patients (58%) developed CRS. 3
• Infections occurred in up to 23% of patients post-CAR T therapy and 24% post-bispecific T-cell engager therapy, complicating the diagnostic picture. 6

Common Diagnostic Pitfalls

• Do not delay empiric antibiotic therapy in critically ill post-transplant patients while awaiting biomarker results if bacterial infection is clinically suspected. 4
• The sensitivity and specificity of procalcitonin for bacterial infection may be altered in the setting of severe CRS. 4
• Post-transplant patients are neutropenic and at high risk for infections, making interpretation of inflammatory markers more challenging. 4
• Premedication protocols may reduce CRS risk and severity, potentially masking early diagnostic features. 1